Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response

Q: What does this research mean for the field?

The cannabinoid CB2 receptor drives trastuzumab resistance in breast cancer and predicts durable anti-HER2 response. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Marta Seijo-Vila; Sofía A Balsinde; Sandra Blasco-Benito; Isabel Tundidor; María Rubert-Hernández; Ana Montero-Calle; Rodrigo Barderas; Laura E. Kilpatrick; Simon Platt; Noémi Karsai; Isabel Philps; Olga M. Antón; Deborah Gómez-Domínguez; Ignacio Pérez de Castro; Carmen González-Lois; Diego García-Fresnadillo; Gala Silvestre-Egea; Antonio Sánchez-López; Esther Ramírez-Medina; María Catalina Rivas Prieto; Belén Almoguera Pérez-Cejuela; Luis Manual Manso; Sandra Zazo; Noemí López-Ejeda; Francisco Palomino-Duque; María Turienzo-Durán; Nuria G Martínez-Illescas; María Salazar-Roa; Sonia Castillo-Lluva; Stephen J. Hill; Manuel Guzmán; Eduardo Pérez-Gómez; C. Pernaut Sánchez

doi:10.5281/zenodo.18945586

Key Points

The research aims to investigate the role of the cannabinoid CB2 receptor in trastuzumab resistance and its potential as a biomarker for anti-HER2 responses.
Analyzed expression levels of CB2 receptors in cancer cells.
Examined trastuzumab response in the presence of CB2 receptor modulation.
Utilized clinical data to correlate CB2 expression with treatment outcomes.
Increased CB2 receptor levels were linked to lower effectiveness of trastuzumab.
Patients with low CB2 expression showed significantly better responses to anti-HER2 therapy.
CB2 receptor modulation affected resistance mechanisms in cancer cells.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Demonstrates the role of CB2 receptor in trastuzumab resistance, suggesting a connection to HER2 treatment outcomes.

Abstract

This manuscript is currently under review in Oncogene

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seijo-Vila et al. (2026) studied this question.

synapsesocial.com/papers/69b3acc502a1e69014cceb5d https://doi.org/10.5281/zenodo.18945586

View Full Paper

Ask AI

Bookmark

Share

Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading